Spinal radiographic progression over 2years in ankylosing spondylitis patients treated with secukinumab : a historical cohort comparison by Braun, J. et al.
RESEARCH ARTICLE Open Access
Spinal radiographic progression over
2 years in ankylosing spondylitis patients
treated with secukinumab: a historical
cohort comparison
J. Braun1* , H. Haibel2, M. de Hooge3, R. Landewé4, M. Rudwaleit5, T. Fox6, A. Readie7, H. B. Richards6, B. Porter7,
R. Martin7, D. Poddubnyy2, J. Sieper2 and D. van der Heijde3
Abstract
Objective: The aim of this study was to compare radiographic progression in patients with ankylosing spondylitis
(AS) treated for up to 2 years with secukinumab (MEASURE 1) with a historical cohort of biologic-naïve patients
treated with NSAIDs (ENRADAS).
Methods: Baseline and 2-year lateral cervical and lumbar spine radiographs were independently evaluated using
mSASSS by two readers, who were blinded to the chronology and cohort of the radiographs. The primary endpoint
was the proportion of patients with no radiographic progression (mSASSS change ≤ 0 from baseline to year 2). The
Primary Analysis Set included patients with baseline (≤ day 30) and post-baseline day 31–743 radiographs. Sensitivity
analyses were performed to assess the robustness of the comparison between the two cohorts, as follows: Sensitivity
Analysis Set 1 included all patients with baseline (≤ day 30) and year 2 (days 640–819) radiographs; Sensitivity Analysis
Set 2 included all patients with baseline and post-baseline (> day 30) radiographs.
Results: A total of 168 patients (84%) from the MEASURE 1 cohort and 69 (57%) from the ENRADAS cohort qualified
for the Primary Analysis Set. Over 2 years, the LS (SE) mean change from baseline in mSASSS for the primary analysis
was 0.55 (0.139) for MEASURE 1 vs 0.89 (0.216) for ENRADAS (p = 0.1852). Mean changes from baseline in mSASSS
were lower in MEASURE 1 vs ENRADAS for the primary and sensitivity analyses. The proportion of patients with no
radiographic progression was consistently higher in the MEASURE 1 vs ENRADAS cohort across all cutoffs for no
radiographic progression (change in mSASSS from baseline to year 2 of ≤ 0, ≤ 0.5, ≤ 1, and ≤ 2), but the differences
were not statistically significant.
Conclusion: Secukinumab-treated patients demonstrated a numerical, but statistically non-significant, higher proportion
of non-progressors and lower change in mSASSS over 2 years versus a cohort of biologic-naïve patients treated
with NSAIDs.
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Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease characterized by inflammation of the sacroiliac
joints and the spine that is eventually followed by
erosions and new bone formation. Irreversible structural
damage occurring as a consequence of new bone for-
mation has a negative impact on patients’ spinal mobility
and physical function and may adversely impact their
quality of life [1, 2]. Thus, next to the reduction of dis-
ease activity, reducing structural damage progression is
an important goal in the treatment of patients with AS.
Drugs that are effective in both abrogation of spinal in-
flammation and protection from radiographic damage
may have a more beneficial impact on physical function
in the long term than drugs that are only effective on
one of these domains.
Nonsteroidal anti-inflammatory drugs (NSAIDs) and
anti-tumor necrosis factor (TNF) agents have both been
demonstrated to improve the signs and symptoms of AS.
Although there is some evidence for a potential benefit
of NSAIDs in decelerating radiographic progression in
AS, when administered continuously [3, 4], there are no
data published to date from prospective, randomized,
and controlled studies with anti-TNF treatments de-
monstrating inhibition of spinal radiographic pro-
gression in AS [5]. As it is considered unethical to
expose patients with AS to placebo treatment for a
2-year period (reported to be the minimum follow-up to
detect radiographic progression in an acceptable number
of patients), historically controlled NSAID-treated co-
hort comparisons have been used [6]. Comparison of
anti-TNF agents with historical cohorts of biologic-naïve
patients treated with NSAIDs has not shown a signifi-
cant added benefit in reducing radiographic progression
at 2 years [7–9].
Interleukin (IL)-17A is a key therapeutic target for the
treatment of AS [10]. Secukinumab, a fully human
monoclonal antibody that directly inhibits IL-17A [11],
was shown to significantly improve the signs and symp-
toms of AS in patients in the MEASURE 1 core trial
(NCT01358175) at 2 years and through 4 years in the
extension study (NCT01863732) [12]. A low radio-
graphic progression rate was also reported from the
MEASURE 1 core trial through 2 years, and this low rate
was sustained through 4 years [12, 13].
This retrospective analysis compared radiographic pro-
gression in the spine of patients with AS treated for up to
2 years with secukinumab (MEASURE 1 cohort) with a
control cohort of biologic-naïve AS patients (i.e., the
effects of nonsteroidal anti-inflammatory drugs [NSAIDs]
on Radiographic Damage in Ankylosing Spondylitis
[ENRADAS; NCT00715091]) to determine if there were
differences in the inhibition of structural damage progres-
sion with the two treatments [12, 14].
Materials and methods
Patients and study design
This was a retrospective comparative cohort study, at
the center of which was an imaging analysis to compare
the progression of structural damage in the spine of
patients with AS treated with secukinumab for up to 2
years versus patients who had not received biologic
therapy. The study compared existing (historical) radio-
graphic data for patients with AS from two cohorts of
patients. Patients were treated in 65 centers in 14
countries in the MEASURE 1 study and in 19 centers in
Germany in the ENRADAS study.
The MEASURE 1 core study was a randomized phase
III trial that enrolled patients ≥ 18 years with AS ful-
filling the modified New York Criteria, and active
disease as indicated by a Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) score ≥ 4 [15] and a
spinal pain score ≥ 4 cm (on a 0–10 cm scale) despite
prior treatment with NSAIDs [16]. Eligible patients were
anti-TNF naïve or had experienced an inadequate re-
sponse to anti-TNF or stopped treatment for safety or
tolerability reasons (i.e., anti-TNF inadequate responders
[anti-TNF IR]) [16]. Patients were randomized to receive a
10mg/kg intravenous (IV) loading dose at baseline, weeks
2 and 4, and then subcutaneous (SC) injections of 150
(IV→150mg) or 75mg (IV→75mg) every 4 weeks (q4wk)
from week 8 [16]. In the placebo-randomized patients,
the same IV-to-SC schedule was administered up to
week 16 (non-responders) or week 24 (responders),
when patients were switched to secukinumab, as pre-
viously described [16].
The ENRADAS study was a randomized trial that
enrolled patients aged 18–65 years fulfilling the modified
New York Criteria and active disease (back pain on a
0–10 numerical rating scale ≥ 4) that justified the
start or continuation of an NSAID and had no con-
traindications for NSAID therapy [14]. Treatment with
anti-TNFs was not permitted before or during the study
[14]. Patients were randomized to treatment with diclo-
fenac either continuously (at least 50% per day of the
maximally recommended daily dose of 150mg diclofenac,
i.e., two pills of 75mg) or on demand for a total period of
2 years, without a washout period for previous NSAID
treatment. Switching to another NSAID was allowed in
case of intolerance or inefficacy; equivalent dosages of
NSAIDs were used in switchers.
Radiographic assessments and endpoints
Lateral cervical and lumbar spine radiographs from both
cohorts were combined and independently re-evaluated
using the mSASSS (range 0–72) scored by two trained
readers who were blinded to the chronology and cohort
of the radiographs. Radiographic progression was based
on the average change from baseline in mSASSS of the
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two assessors over 2 years. A third trained reader served
as an independent adjudicator, who evaluated the top
10% of cases with the highest difference in change in
total mSASSS scores between the two primary readers.
In the top 10% of cases requiring adjudication, the
reading of the third reader was used, with the average
readings of the primary readers being used for the
remaining 90% of cases.
The primary endpoint was the proportion of patients
with no radiographic progression (mSASSS change from
baseline to year 2 of ≤ 0) in the MEASURE 1 vs the
ENRADAS cohort. Secondary endpoints included a
change from baseline in mSASSS to year 2 and the pro-
portion of patients with mSASSS change from baseline
to year 2 of ≤ 0.5, ≤ 1, and ≤ 2.
For MEASURE 1, a radiograph performed up to day
30 was considered as baseline; for ENRADAS, the first
radiograph determined the baseline. All other study days
(e.g., week 104) were labeled relative to day 1. The
Primary Analysis Set included all patients with baseline
(target day 1; window up to day 30) and post-baseline
up to week 104 (target day 729; window day 31 to day
743) radiographs (MEASURE 1, N = 168; ENRADAS,
N = 69). Post-baseline was defined as the measurement
closest to the target date. The post-baseline window of
day 31 to day 743 was chosen to align with the analysis
visit window used in the MEASURE 1 study. In addition,
day 743 was chosen as the upper limit for the
post-baseline radiograph as 43.4% (53/122) of patients in
ENRADAS had a radiograph window greater than 2
years. These patients were not included in the analysis
as there would be an increased likelihood of detecting
radiographic progression compared with windows less
than 2 years. Patients with post-baseline radiographs
closer to the lower limit of the window (i.e., day 31)
would also have reduced likelihood of showing radio-
graphic progression.
Statistical analyses
Demographics and baseline characteristics of the two
cohorts were summarized and compared. Progressors
and non-progressors as per mSASSS changes from base-
line with different definitions for no-progression were
evaluated using a logistic regression model, with the
cohort as a factor and baseline mSASSS as a covariate.
Change in mSASSS from baseline to 2 years was cal-
culated as least-squares (LS) mean (standard error [SE])
using an analysis of covariance (ANCOVA) model, with
the cohort as a factor and baseline mSASSS as a co-
variate. Cumulative probability plots were generated for
the change in mSASSS values from baseline.
During the conduct of the study, it became apparent
that there were differences in the timing of the post-
baseline X-ray in the MEASURE 1 and ENRADAS
cohorts, which meant that some patients were treated
for less than or more than 2 years at the time of their
post-baseline imaging assessment. To address this issue,
sensitivity analyses were performed to assess the robust-
ness of the comparison between the two cohorts using
the following sets: Sensitivity Analysis Set 1 included all
patients with baseline (≤ day 30) and year 2 ± 3months
(days 640–819) radiographs; Sensitivity Analysis Set 2
included all patients with baseline (≤ day 30) and
post-baseline (> day 30) radiographs (paired radiographs
were analyzed adjusted for the difference in time
between baseline and post-baseline radiographs as an
additional covariate in the model).
An exploratory analysis was added to evaluate inter-
reader reliability using the intra-class correlation co-
efficient (ICC) for mean change from baseline in mSASSS.
The smallest detectable change (SDC) for mean change
from baseline in mSASSS was calculated based on the
95% level of agreement between the two readers.
Results
Patients and radiograph measurements
A total of 168 patients (84%) from the MEASURE 1
cohort and 69 patients (57%) from the ENRADAS
cohort qualified for the Primary Analysis Set; 175 (87%)
patients from the MEASURE 1 cohort and 78 (64%)
patients from the ENRADAS cohort qualified for Sen-
sitivity Analysis Set 1. Mean age, gender, and mSASSS
were comparable across cohorts and analysis sets
(Table 1) At baseline, patients had higher mean
C-reactive protein (CRP) levels (18.3 vs 8.8), and a
lower prevalence of smoking (25.0% vs 44.9%) in the
MEASURE 1 vs ENRADAS cohorts, respectively. A
higher rate of corticosteroid use was observed in
ENRADAS (63.9%) vs MEASURE 1 (12.9%) in the full
analysis set (i.e., Sensitivity Analysis Set 2).
Distributions of the timing of post-baseline radio-
graphs for the full analysis sets of MEASURE 1 (N =
201) and ENRADAS (N = 122) are shown in Fig. 1.
The mean (SD) number of days between baseline and
post-baseline radiographs for the MEASURE 1 and
ENRADAS cohorts were 659.6 (170.8) and 695.1
(56.1) days for the Primary Analysis Set, 737.0 (18.3)
and 723.5 (29.3) days for Sensitivity Analysis Set 1,
and 688.0 (153.4) and 775.9 (135.6) days for Sensitivity
Analysis Set 2.
Change in mSASSS from baseline
Primary analysis
The cumulative probability plot illustrates the change in
mSASSS from baseline to 2 years for MEASURE 1 and
ENRADAS patients in the Primary Analysis Set (Fig. 2a).
The proportion of patients with no radiographic pro-
gression (LS mean change in mSASSS from baseline to
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year 2 ≤ 0) was 60.7% in the MEASURE 1 cohort vs 52.2%
in the ENRADAS cohort (p = 0.2430; Table 2).
Secondary analyses
The proportion of patients with no radiographic pro-
gression was consistently higher in the MEASURE 1
vs ENRADAS across all cutoffs for no radiographic
progression (change in mSASSS from baseline to year
2 of ≤ 0, ≤ 0.5, ≤ 1 and ≤ 2; Table 2), although the
results were not statistically significant. Over 2 years,
the LS (SE) mean change from baseline in mSASSS
for the Primary Analysis Set was 0.55 (0.139) for
MEASURE 1 vs 0.89 (0.216) for ENRADAS (p = 0.1852;
Table 3).
Cumulative probability plots illustrating the change
in mSASSS from baseline using Sensitivity Analysis Set
1 is shown in Figs. 2b. Differences in the LS mean
change from baseline in mSASSS were lower in the
MEASURE 1 vs ENRADAS cohorts across all of the
sets analyzed (Table 3).
Table 1 Demographics and baseline characteristics of patients in the MEASURE 1 and ENRADAS cohorts
MEASURE 1 ENRADAS
Characteristic Primary Analysis
Set (N = 168)a
Sensitivity Analysis
Set 1 (N = 175)b
Sensitivity Analysis
Set 2 (N = 201)
Primary Analysis
Set (N = 69)a
Sensitivity Analysis
Set 1 (N = 78)b
Sensitivity Analysis
Set 2 (N = 122)
mSASSS 9.6 ± 14.1 9.0 ± 14.05 6.4 ± 10.4 9.9 ± 13.8 9.8 ± 13.3 7.9 ± 10.5
CRP (mg/L) 18.3 ± 23.4 18.1 ± 22.1 17.5 ± 21.1 8.8 ± 9.7 10.1 ± 11.5 10.1 ± 12.0
Smoker, n (%) 42 (25.0) 33 (18.9) 45 (22.4) 31 (44.9) 35 (44.9) 56 (46.3)
Time since diagnosis, years 7.2 ± 8.0 6.3 ± 7.0 6.9 ± 7.7 10.3 ± 11.1 8.9 ± 10.5 8.6 ± 10.1
NSAID use, n (%) 166 (98.8) 174 (99.4) 199 (99.0) 69 (100) 78 (100) 122 (100)
Corticosteroid use, n (%) 23 (13.7) 23 (13.1) 26 (12.9) Not available Not available 78 (63.9)c
Age in years 41.0 ± 12.6 40.3 ± 12.8 41.3 ± 12.6 42.6 ± 10.8 42.0 ± 10.4 42.8 ± 10.2
Male, n (%) 123 (73.2) 122 (69.7) 141 (70.1) 46 (66.7) 56 (71.8) 84 (68.9)
HLA-B27 positive, n (%) 136 (82.9) 139 (81.8) 155 (79.5) 61 (88.4) 72 (92.3) 110 (90.2)
Data are mean ± standard deviation unless otherwise stated
CRP C-reactive protein, ENRADAS effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on Radiographic Damage in Ankylosing Spondylitis, HLA human
leukocyte antigen, mSASSS modified Stoke Ankylosing Spondylitis Spinal Score, NSAID nonsteroidal anti-inflammatory drugs
aData are shown for patients with baseline and days 31–743 radiographs
bData are shown for patients with baseline and days 640–819 radiographs
cCorticosteroid use from the total ENRADAS study population—personal communication from D Poddubnyy
Fig. 1 Distributions of the timings of post-baseline radiograph measurements for MEASURE 1 and ENRADAS
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A
B
Fig. 2 Cumulative probability plot for the change from baseline to year 2 in MEASURE 1 and ENRADAS cohorts using a Primary Analysis
Seta, b Sensitivity Analysis Set 1b.
aIncludes patients with baseline (≤ day 30) and days 31–743 radiographs; bIncludes patients with baseline (≤ day 30) and day 640–819 radiographs.
mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score
Table 2 Proportion of patients with no radiographic progression according to mSASSS cut-offs of ≤0, ≤0.5, ≤1.0, and ≤ 2.0
MEASURE 1 (N = 201);
ENRADAS (N = 122)
n (% of N)
No radiographic progression, % of patients
Δ ≤0 Δ ≤0.5 Δ ≤1.0 Δ ≤2.0
















Sensitivity analysis set 2 (All patients, time-
adjusted)a










BL Baseline, E ENRADAS, M MEASURE 1, mSASSS Modified stoke ankylosing spondylitis spinal score, n Number of patients per cohort in each analysis set, N Total
number of patients per cohort
aAll patients with BL (≤ Day 30) and post-BL (> Day 30) radiographs, adjusted for difference in time between BL and post-BL radiographs
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Reader reliability
The ICC for the mean change from baseline in mSASSS
was 0.17 in the Primary Analysis Set. The SDC with a 95%
level of agreement was 3.7 for the Primary Analysis Set.
Discussion
The progression rate of patients treated with secukinu-
mab found in this study was in the same range as in the
recent publications [12–14]. Evaluating the Primary
Analysis Set of this study, we found a numerically higher
proportion of radiographic non-progressors (defined as
an mSASSS change from baseline ≤ 0 at year 2 [primary
outcome]) among secukinumab-treated patients (MEAS-
URE 1) compared with controls from a cohort of
biologic-naïve NSAID-treated patients (ENRADAS) over
2 years. However, differences between these groups were
not statistically significant. The proportion of non-pro-
gressors was consistently higher in the MEASURE 1 vs
ENRADAS cohorts across all sets analyzed and regard-
less of the mSASSS cutoff used (mSASSS change from
baseline ≤ 0, ≤ 0.5, ≤ 1 or ≤ 2 at year 2). In this analysis,
around 82–85% of patients in MEASURE 1 exhibited in-
hibition of radiographic progression using an mSASSS
cutoff of ≤ 2 at year 2 across all sets analyzed compared
with around 71–76% for ENRADAS.
It is possible that the differences in time intervals
between baseline and 2-year radiographs in MEASURE 1
vs ENRADAS may have confounded the results in the
Primary Analysis Set owing to the wide window for
post-baseline radiographs. To address this limitation,
Sensitivity Analysis Set 1 was included with a narrow
window for the post-baseline radiograph around 2 years
(i.e., days 640–819). The results of this analysis confirmed
a higher proportion of radiographic non-progressors in
MEASURE 1 (81.5%) vs ENRADAS (75.6%). Results of
Sensitivity Analysis Set 2, which was adjusted for the
differences in timings of the baseline and post-baseline
radiographs, confirmed these findings with an even higher
rate of radiographic non-progressors in MEASURE 1
(84.6%) vs. ENRADAS (75.4%). A cutoff of 2 years
was chosen in the current study as some patients in
ENRADAS had their post-baseline radiographs after 2
years, resulting in a longer radiographic interval compared
with MEASURE 1.
Historically controlled cohort comparisons with anti-
TNF agents have shown no benefit of anti-TNF therapies
compared with NSAIDs on structural progression after
2 years (range of mean change in mSASSS was 0.8–0.9
in patients treated with anti-TNF agents vs 0.9–1.0
NSAID-treated biologic-naïve patients) [7–9]. While
prospectively controlled studies with anti-TNF agents
have not demonstrated a reduction in radiographic
structural progression over 2 years, recent 4-year data
with certolizumab treatment demonstrated a low rate of
mSASSS progression, with non-progression seen in
80.6% of patients [17]. Longitudinal data from cohort
studies have suggested that a longer duration of treatment
with anti-TNFs of 4 to 8 years may be required before a
positive effect on radiographic structural progression is
observed [18–21].
In the MEASURE 1 study, treatment with secukinumab
resulted in a low mean change in mSASSS from baseline
to 2 years of 0.3 (SD 2.53) overall, and 0.38–0.52 among
patients with known predictors of radiographic progres-
sion at baseline, such as syndesmophytes or elevated CRP
[12]. In the extension study, 79% of patients treated with
secukinumab 150mg reported no radiographic progres-
sion (change in mSASSS from baseline < 2) at 4 years [13].
Further research is needed to understand the im-
pact of IL-17A inhibition with secukinumab on spinal
disease progression in AS patients. Since no direct
comparison between anti-TNF agents and IL-17
blocking agents has been performed so far it can be
expected that SURPASS (NCT03259074), an ongoing
head-to-head study powered to compare differences
in spinal radiographic progression with secukinumab
compared with biosimilar adalimumab, will help to
address this [22].
Due to the retrospective nature of this study and lack
of randomization/stratification of patients between the
study cohorts, there was some heterogeneity between
the two cohorts (i.e., higher CRP levels, lower cortico-
steroid use, and a lower proportion of smokers in the
MEASURE 1 vs ENRADAS cohorts). This may be
viewed as a limitation of the study, as patient and disease
Table 3 LS mean change from Baseline in mSASSS and the different in LS means in MEASURE 1 vs ENRADAS
MEASURE 1 (N = 201);
ENRADAS (N = 122)
n (% of N)
LS mean change (SE)
from BL in mSASSS
Difference in LS means (SE)
(MEASURE 1 vs. ENRADAS)
p value
Primary analysis set (BL to Days 31–743) M: 168 (84%); E: 69 (57%) M: 0.55 (0.139); E: 0.89 (0.216) −0.34 (0.257); p = 0.1852
Sensitivity analysis set 1 (BL to Days 640–819) M: 178 (89%); E: 82 (67%) M: 0.69 (0.153); E: 0.72 (0.225) −0.03 (0.272); p = 0.9175
Sensitivity analysis set 2, (All patients)a M: 201 (100%); E: 122 (100%) M: 0.68 (0.168); E: 0.99 (0.217) −0.31 (0.280); p = 0.2636
BL Baseline, E ENRADAS, LS Least squares, M MEASURE 1, mSASSS Modified stoke ankylosing spondylitis spinal score, SE Standard error, n Number of patients per
cohort in each analysis set, N Total number of patients per cohort
aAll patients with BL (≤ Day 30) and post-BL (> Day 30) radiographs, adjusted for the difference in time between BL and post-BL radiographs
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characteristics at baseline can increase the risk of struc-
tural progression [23–25]. In addition to the timings of
the post-baseline radiographs, the differences in time
between when the two studies were performed may
also have confounded the results, as there may have
been differences between the populations owing to
changes in the environment, lifestyle, and other un-
known factors.
Conclusions
The key findings of this analysis showed that over 2 years,
secukinumab-treated patients demonstrated a numerically
higher proportion of radiographic non-progressors and a
numerically, but statistically non-significant, lower change
in mSASSS compared with biologic-naïve NSAID-treated
patients in the Primary Analysis Set. Given the variability
in timing between the baseline and post-baseline X-ray
assessments in the pre-defined Primary Analysis Set,
sensitivity analyses were conducted on another set of
patients who were confirmed as having closer to 2 years of
treatment prior to the post-baseline imaging assessment.
The well-powered SURPASS randomized controlled trial
will examine the impact of IL-17A inhibition with secuki-
numab on spinal disease progression in AS patients and
will provide a more robust answer.
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